Synergistic effect of Addie injection on pemetrexed combined with nedaplatin in the treatment of advanced non-small cell lung cancer

doi:10.12092/j.issn.1009-2501.2018.03.014

Abstract

Abstract:

AIM: To investigate whether Addie injection can improve the efficacy of pemetrexed combined with nedaplatin in the treatment of advanced non-small cell lung cancer. METHODS: Eighty-six cases of advanced non-small cell lung cancer patients were divided into the study group and the control group, 43 cases in each group. The control group was treated with pemetrexed combined with nedaplatin. The study group was treated with Addie injection on the basis of the control group. The clinical efficacy of the two groups was compared. The changes of serum immune indexes before and after treatment in two groups were detected. The immune indexes included CD3+, CD4+, CD4+/CD8+, IgM, IgA, IgG. Adverse reactions of two groups in the course of treatment were observed. RESULTS:The control rate and effective rate of the study group were higher than those of the control group. But the difference was not statistically significant (P>0.05). The levels of CD3+, CD4+, CD4+/CD8+, IgA and IgG in the control group were significantly decreased after treatment (P<0.05). The levels of CD3+, CD4+, CD4+/CD8+, IgA and IgG after treatment in the study group were significantly higher than those in the control group. The difference was statistically significant (P<0.05). The incidence of gastrointestinal reaction, white blood cell reduction, abnormal liver and kidney function in the study group was significantly lower than that in the control group. The difference was statistically significant (P<0.05). CONCLUSION: Addie injection has a synergistic and attenuated effect on pemetrexed combined with nedaplatin in the treatment of advanced non-small cell lung cancer.

Key words: Addie injection, pemetrexed, nedaplatin, non-small cell lung cancer

CLC Number:

R734.2

LI Weiwen, LI Yuan, SUN Lei, HUANG Gongcai, ZHAO Zhongwei. Synergistic effect of Addie injection on pemetrexed combined with nedaplatin in the treatment of advanced non-small cell lung cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 325-328.

References

［1］胡毅,陶海涛.晚期非小细胞肺癌的药物治疗进展［J］.中国药物应用与监测,2014,11(6):329-333.
［2］杨国旺, 王皓, 韩磊, 等. 中医辨证论治方案联合化疗治疗晚期非小细胞肺癌91例临床观察［J］. 中医杂志, 2014, 55(3): 209-213.
［3］宫丹, 王铭宏, 张爽, 等. 艾迪注射液联合含紫杉醇的化疗方案治疗Ⅲ～Ⅳ期非小细胞肺癌42例［J］. 解放军医药杂志, 2014, 6(8): 81-84.
［4］石远凯, 孙燕. 临床肿瘤内科手册［M］. 6版. 人民卫生出版社, 2015: 178-181.
［5］Watanabe H, Okada M, Kaji Y, et al. New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)［J］. Gan To Kagaku Ryoho, 2009, 36(13): 2495-2501.
［6］马亚梅. 培美曲塞联合顺铂治疗晚期非小细胞肺癌的疗效观察［J］. 实用癌症杂志, 2015, 30(2): 205-207.
［7］杨锭洪, 孟凡军, 林长裕. 奈达铂联合多西他赛治疗非小细胞肺癌的临床效果及其安全性评价［J］. 中国医药导报, 2014, 11(22): 73-76.
［8］刘晓文. 培美曲塞联合奈达铂治疗晚期非小细胞肺癌的临床疗效观察［J］. 中国现代药物应用, 2016, 10(3): 124-125.
［9］蔡晓平, 金元虹, 朱晓瑜, 等. 艾迪注射液辅助GP化疗方法对晚期非小细胞肺癌近期疗效评价［J］. 中国免疫学杂志, 2015, 31(10): 1397-1399.
［10］何敏, 周浴, 邝军, 等. 鸦胆子油乳联合艾迪注射液对非小细胞肺癌化疗患者免疫功能的影响［J］. 中国现代医学杂志, 2015, 25(7): 47-50.
［11］张晓春. 艾迪注射液联合GP方案治疗非小细胞肺癌临床观察［J］. 辽宁中医药大学学报, 2016, 18(2): 173-175.
［12］何志锋, 刘瑜, 吴原波. 艾迪注射液联合多西他赛、卡铂化疗方案对非小细胞肺癌的近期疗效［J］. 中华中医药学刊, 2016, 34(6): 1459-1461.
［13］马亚梅, 姜西玲. 艾迪注射液联合GP化疗方案对非小细胞肺癌患者的影响研究［J］. 实用心脑肺血管病杂志, 2016, 24(6): 89-92.
［14］刘雷, 丁琛琛, 胡胜, 等. 非小细胞肺癌免疫功能与TKI治疗疗效的关系［J］. 中国肿瘤, 2016, 25(10): 811-815.
［15］王政江,王德霞,窦慧慧,等. P53、MDM-2蛋白在肺癌中的表达及其与肺癌临床病理特征的关系研究［J］.疑难病杂志,2017,16(10):1047-1049,1053.
［16］杨姗姗,刘天明,袁宝山,等.B细胞及其IgG亚类在非小细胞肺癌患者中的分布及临床意义［J］.中华微生物学和免疫学杂志,2015,35(11):816-820.

[1]	HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle. Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
[2]	ZHANG Kexin, JIA Wenjing, CUI Jiawen, AO Luyao, ZHOU Fang, WANG Guangji, LIU Jiali. Advances in the research and clinical application of the third generation EGFR TKIs in the treatment of non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1016-1030.
[3]	PEI Qinghua, SUN Jianli. Research progress of Osimertinib acquired resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 105-112.
[4]	WEI Weitian, CHEN Sheng, WANG Liang, ZENG Jian. Breviscapine induced the apoptosis of non-small cell lung cancer A549 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 618-624.
[5]	WANG Haili, GONG Tianxiao, ZHOU Shixia, MEI Jiazhuan, ZHANG Zhongmian. Efficacy and safety of third-line treatment with mesylate apatinib in patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 567-572.
[6]	YANG Ke, LI Junling, DU Bin, TIAN Zhongqiu, JING Xiujuan. Single-arm,one-center, exploratory clinical trial of albumin-bound paclitaxel second and more line therapy for advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1281-1286.
[7]	WANG Haixia, LIU Xingan, HOU Jiyuan, GONG Zhe, SHAN Guoyong. Influence of genetic variation of KDR on clinical outcomes of advanced NSCLC treated by first line bevacizumab regimens [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 802-808.
[8]	ZHANG Zhaowei, FANG Tianzi, LIU Jianxia. Study of the efficacy and safty of irinotecan combined with nedaplatin versus topotecan combined with nedaplatin in treatment of small lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 943-947.
[9]	BAO Zhi-jian, CHEN Dao-bao, LI Bo-ying. Research on the therapeutic effect and adverse reactions of combination chemotherapy with NVB and TXT on non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(8): 916-919.
[10]	PENG Ye, WANG Mei-qin, XIE Na, LI Yan, LU Hai-yan, LI Bing-mao. Randomized study of thalidomide in combination with TP chemotherapy for the treatment of advanced non-small-cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(3): 317-321.
[11]	CHEN Dong-yun, ZHAO Wen-ying, JI Zhao-ning. Clinical study comparing pemetrexed plus carboplatin with gemcitabine plus carboplatin as first-line treatment in patients with advanced nonsquamous non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(12): 1401-1405.
[12]	XU Feng-hua, GUO Rong-rong, LI Xin, LONG Li-yan, ZHANG Gui-yun. Relationship between ERCC1 expression and sensitivity of platinum-based chemotherapy in NSCLC: a systematic review [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 45-50.
[13]	ZHAO Wen-ying, CHEN Dong-yun, CHEN Jing-hua. Observation of short-term therapeutic and adverse effect of lentinan and gemcitabine plus cisplatin as the first-line treatment for advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 71-77.
[14]	GU Liang, ZHAO Tian, QIN Guang-yue. Comparison of gefitinib and pemetrexed in treatment of advanced non-small cell lung cancer patients who have failed to first-line chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(5): 569-572.
[15]	HUA Zhi-hui, FANG Wen-zheng, ZHAO Zhong-quan, XIE Fang-wei, OU YANG Xue-nong, SONG Hong-tao. Association study of ERCC1 and ERCC4 genetic polymorphism with response and survival in non-small cell lung cancer patients treated with cisplatin-based chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(7): 772-778.